Efficacy, safety and prognostic factors of camrelizumab plus carboplatin and pemetrexed chemotherapy in advanced lung adenocarcinoma patients.
Lv J, Zhang W, Deng R, Chen Y, Liu M, Zhang Z, Wang Q, He Y, Liu Y, Wang F, Lv Z, Zhou H, Li C, Zhang T, Fu Y, Zhao X, Bao Q, Miao Y, Wang L, Huang M, Zhang C.
Lv J, et al. Among authors: zhou h.
J Clin Pharm Ther. 2022 Aug;47(8):1257-1263. doi: 10.1111/jcpt.13664. Epub 2022 Apr 9.
J Clin Pharm Ther. 2022.
PMID: 35397125